CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Join Russell 3000® Index

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

23 May 2024 17:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

22 May 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

20 May 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

25 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

11 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

09 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

04 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

28 Mar 2024 08:05:47 By Nasdaq GlobeNewswire

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

13 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

12 Dec 2023 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

28 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

09 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

04 Nov 2023 08:00:00 By Nasdaq GlobeNewswire